GE

Genomictree Inc.

A molecular diagnostics company developing tests for the early detection of cancer.

228760 | KO

Overview

Corporate Details

ISIN(s):
KR7228760005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노10로 44-6, 대전광역시

Description

Genomictree Inc. is a molecular diagnostics company that develops and commercializes products for the early detection and diagnosis of cancer. The company specializes in epigenomics, utilizing its proprietary genomic-scale discovery tools to identify DNA methylation biomarkers. Its flagship product line, EarlyTect®, offers non-invasive tests for the early screening of colorectal, lung, and bladder cancers. Additionally, Genomictree provides AccuraTect™, a companion diagnostic test for cancer. The company's mission is to improve patient quality of life and reduce medical costs through accessible and accurate early-stage cancer detection.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2026-01-12 00:00
자기주식처분결과보고서
Korean HTML 17.0 KB
2026-01-12 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.6 KB
2026-01-12 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.6 KB
2026-01-12 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.6 KB
2026-01-12 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.7 KB
2026-01-09 00:00
주요사항보고서(자기주식처분결정)
Korean HTML 30.6 KB
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean HTML 4.1 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean HTML 1.6 MB
2025-06-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.7 KB
2025-06-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.7 KB
2025-06-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.5 KB
2025-06-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.5 KB
2025-06-16 00:00
자기주식처분결과보고서
Korean HTML 16.7 KB
2025-06-11 00:00
주요사항보고서(자기주식처분결정)
Korean HTML 29.1 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean HTML 1.3 MB

Automate Your Workflow. Get a real-time feed of all Genomictree Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genomictree Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genomictree Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CAMBRIDGE COGNITION HOLDINGS PLC Logo
Develops digital solutions and a platform for CNS clinical trials to assess brain health.
United Kingdom
COG
A clinical-stage biopharmaceutical company developing novel cancer therapeutics.
Japan
4575
Captor Therapeutics S.A. Logo
Develops Targeted Protein Degradation therapies for cancer and autoimmune diseases.
Poland
CTX
Cardiff Oncology, Inc. Logo
A clinical-stage biotech developing cancer therapies that inhibit Polo-like kinase 1.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
Develops AI-powered epigenetic and genetic tests for early heart disease detection.
United States of America
CDIO
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing treatments for Central Nervous System disorders.
United States of America
SAVA
Celcuity Inc. Logo
Clinical-stage biotech developing targeted therapies for multiple solid tumors.
United States of America
CELC
Develops and manufactures cellulose-based nonwoven fabrics for the cosmetics sector.
South Korea
318160
CEL SCI CORP Logo
Clinical-stage biotech developing immunotherapies for cancer and infectious diseases.
United States of America
CVM
Celyad Oncology SA Logo
Biotechnology company developing innovative CAR-T cell therapies to treat cancer.
Belgium
CYAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.